Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 3.86 is 40% below its 5-year average of 6.48, near the low end of its 5-year range (3.86–13.74).
As of the fiscal period ended Tuesday, June 30, 2026. 9.68% below its 12-month average of 4.28.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.86.
QUICK RATIO (ACID-TEST)
3.86
QUICK RATIO (ACID-TEST) AVG TTM
4.28
QUICK RATIO (ACID-TEST) AVG 3Y
5.23
QUICK RATIO (ACID-TEST) AVG 5Y
6.48
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.68%
CURRENT VS 3Y AVG
-26.22%
CURRENT VS 5Y AVG
-40.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 599 covered companies
CURRENT VS SECTOR MEDIAN
+29.16%
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$744.51M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.28
3Y Avg
5.23
5Y Avg
6.48
Market Cap
$743.69M
Quick Ratio (Acid-Test)
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$748.55M
Quick Ratio (Acid-Test)
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$755.39M
Quick Ratio (Acid-Test)
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
Market Cap
$722.78M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$712.45M
Quick Ratio (Acid-Test)
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$766.58M
Quick Ratio (Acid-Test)
1.52
TTM Avg
0.88
3Y Avg
1.36
5Y Avg
2.75
Market Cap
$768.46M
Quick Ratio (Acid-Test)
13.29
TTM Avg
5.16
3Y Avg
5.49
5Y Avg
4.89
Market Cap
$773.03M
Quick Ratio (Acid-Test)
5.16
TTM Avg
4.89
3Y Avg
3.82
5Y Avg
4.31
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $744.51M | 3.86 | 4.28 | 5.23 | 6.48 |
| Candel Therapeutics, Inc. (CADL)vs › | $743.69M | 16.09 | 8.04 | 7.87 | 9.13 |
| Design Therapeutics, Inc. (DSGN)vs › | $748.55M | 18.86 | 23.23 | 26.78 | 32.61 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.39M | 9.39 | 11.79 | 11.79 | 11.79 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $722.78M | 19.31 | 14.05 | 7.67 | 5.91 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $712.45M | 0.95 | 4.92 | 2.98 | 5.72 |
| Mesa Laboratories, Inc. (MLAB)vs › | $766.58M | 1.52 | 0.88 | 1.36 | 2.75 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | 13.29 | 5.16 | 5.49 | 4.89 |
| Geron Corporation (GERN)vs › | $773.03M | 5.16 | 4.89 | 3.82 | 4.31 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $703.70M | 0.84 | 1.18 | 1.08 | 1.08 |
Quick Ratio
3.86
Excludes inventory
Current Ratio
4.48
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 3.86 |
| 2026-03-31 | 4.07 |
| 2025-12-31 | 4.42 |
| 2025-09-30 | 4.48 |
| 2025-06-30 | 4.55 |
| 2025-03-31 | 4.95 |
| 2024-12-31 | 5.21 |
| 2024-09-30 | 5.47 |
| 2024-06-30 | 6.38 |
| 2024-03-31 | 6.01 |
| 2023-12-31 | 5.89 |
| 2023-09-30 | 6.06 |
| 2023-06-30 | 6.70 |
| 2023-03-31 | 6.30 |
| 2022-12-31 | 8.28 |
| 2022-09-30 | 9.51 |
| 2022-06-30 | 9.40 |
| 2022-03-31 | 9.37 |
| 2021-12-31 | 12.04 |
| 2021-09-30 | 13.74 |
| 2021-06-30 | 6.76 |
| 2021-03-31 | 6.71 |
| 2020-12-31 | 6.99 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
